Data protection Impressum

Life sciences

The Munich- and Lausanne-based biotech secures Europe’s largest-ever Series C financing to accelerate development of next-generation antibody-drug conjugates.

Tubulis raises EUR 308 million to advance ADC therapies and expand its clinical pipeline

29 October 2025

Neurotechnology company ONWARD Medical extends its cash runway through 2026 and prepares to expand commercialization and clinical development of its ARC Therapy systems.

ONWARD Medical raises over EUR 50 million to advance spinal cord therapies

27 October 2025

Adaptyv raises USD 8 million to accelerate AI-powered protein validation

27 October 2025

Vaud-based FemTech company Aspivix begins commercial rollout in Southern California and New York following strong clinical validation and growing U.S. demand.

Aspivix launches its breakthrough Carevix device in the United States

21 October 2025

Lausanne-based biotech ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.

ADC Therapeutics raises USD 60 million to strengthen oncology portfolio

21 October 2025

EssilorLuxottica’s acquisition of RetinAI strengthens its medtech portfolio with advanced AI and data-driven solutions for eye disease management.

EssilorLuxottica acquires Bern-based RetinAI to accelerate AI-powered eye health innovation

20 October 2025

A CHF 2.1 million endowed professorship will strengthen data-driven cancer medicine at the University of Bern and Inselspital.

New endowed professorship to advance digital cancer medicine in Bern

13 October 2025

UCB is investing more than CHF 100 million in its Bulle site to boost capacity, create new jobs, and strengthen sustainable production.

UCB invests over CHF 100 million to expand its biopharmaceutical site in Bulle

7 October 2025

HemostOD has raised CHF 4.3 million in a Seed-extension round to accelerate the industrialization of its donor-free, off-the-shelf human blood platelets. The new funding marks a key milestone for the EPFL spin-off as it transitions from proof-of-concept to large-scale manufacturing.

HemostOD raises CHF 4.3 million to scale production of universal blood platelets

6 October 2025

Geneva-based medtech company Spineart has secured a CHF 25 million investment from long-standing shareholders Gimv and EGS Beteiligungen (EGSB) to fuel its next phase of growth and global expansion.

Spineart raises CHF 25 million to accelerate global expansion and innovation

6 October 2025

1 2 3 4 5 … 45